La prévention comme cœur de cible - ACHAT - OC 15,6€
Nous initions ce matin Valbiotis avec une recommandation ACHAT et un OC de 15,6€. La société développe des compléments santé dans la prévention des pathologies métaboliques chroniques. Les recherches de Valbiotis se fondent sur sa plateforme R&D propriétaire visant à développer des complexes poly-moléculaires « first-in-class » qui suite à des études cliniques pourront obtenir « l’allégation de santé ». La trésorerie actuelle permettra de financer à minima le développement complet de Valedia® afin d’obtenir l’allégation santé dans le pré-diabète. Un partenariat avec un acteur Agro-alimentaire ou Pharmaceutique est à entrevoir post résultats.Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.